2
|
Moutton S, Fergelot P, Naudion S, Cordier MP, Solé G, Guerineau E, Hubert C, Rooryck C, Vuillaume ML, Houcinat N, Deforges J, Bouron J, Devès S, Le Merrer M, David A, Geneviève D, Giuliano F, Journel H, Megarbane A, Faivre L, Chassaing N, Francannet C, Sarrazin E, Stattin EL, Vigneron J, Leclair D, Abadie C, Sarda P, Baumann C, Delrue MA, Arveiler B, Lacombe D, Goizet C, Coupry I. Otopalatodigital spectrum disorders: refinement of the phenotypic and mutational spectrum. J Hum Genet 2016; 61:693-9. [PMID: 27193221 DOI: 10.1038/jhg.2016.37] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2015] [Revised: 03/15/2016] [Accepted: 03/15/2016] [Indexed: 11/09/2022]
Abstract
Otopalatodigital spectrum disorders (OPDSD) constitute a group of dominant X-linked osteochondrodysplasias including four syndromes: otopalatodigital syndromes type 1 and type 2 (OPD1 and OPD2), frontometaphyseal dysplasia, and Melnick-Needles syndrome. These syndromes variably associate specific facial and extremities features, hearing loss, cleft palate, skeletal dysplasia and several malformations, and show important clinical overlap over the different entities. FLNA gain-of-function mutations were identified in these conditions. FLNA encodes filamin A, a scaffolding actin-binding protein. Here, we report phenotypic descriptions and molecular results of FLNA analysis in a large series of 27 probands hypothesized to be affected by OPDSD. We identified 11 different missense mutations in 15 unrelated probands (n=15/27, 56%), of which seven were novel, including one of unknown significance. Segregation analyses within families made possible investigating 20 additional relatives carrying a mutation. This series allows refining the phenotypic and mutational spectrum of FLNA mutations causing OPDSD, and providing suggestions to avoid the overdiagnosis of OPD1.
Collapse
Affiliation(s)
- Sébastien Moutton
- CHU Bordeaux, Hôpital Pellegrin, Department of Medical Genetics, Centre de Référence des Anomalies du Développement Embryonnaire, Bordeaux cedex, France.,Université de Bordeaux, INSERM U1211, Laboratoire Maladies Rares: Génétique et Métabolisme, Bordeaux, France
| | - Patricia Fergelot
- CHU Bordeaux, Hôpital Pellegrin, Department of Medical Genetics, Centre de Référence des Anomalies du Développement Embryonnaire, Bordeaux cedex, France.,Université de Bordeaux, INSERM U1211, Laboratoire Maladies Rares: Génétique et Métabolisme, Bordeaux, France.,Plateforme Génome Transcriptome, Centre de Génomique Fonctionnelle de Bordeaux, Université de Bordeaux, Bordeaux, France
| | - Sophie Naudion
- CHU Bordeaux, Hôpital Pellegrin, Department of Medical Genetics, Centre de Référence des Anomalies du Développement Embryonnaire, Bordeaux cedex, France
| | - Marie-Pierre Cordier
- CHU Lyon, Hôpital Femme-Mère-Enfant, Department of Medical Genetics, Bron cedex, France
| | - Guilhem Solé
- Université de Bordeaux, INSERM U1211, Laboratoire Maladies Rares: Génétique et Métabolisme, Bordeaux, France.,CHU Bordeaux, Hôpital Pellegrin, Department of Neurology, Fédération des Neurosciences Cliniques, Bordeaux, France
| | - Elodie Guerineau
- Université de Bordeaux, INSERM U1211, Laboratoire Maladies Rares: Génétique et Métabolisme, Bordeaux, France
| | - Christophe Hubert
- Plateforme Génome Transcriptome, Centre de Génomique Fonctionnelle de Bordeaux, Université de Bordeaux, Bordeaux, France
| | - Caroline Rooryck
- CHU Bordeaux, Hôpital Pellegrin, Department of Medical Genetics, Centre de Référence des Anomalies du Développement Embryonnaire, Bordeaux cedex, France.,Université de Bordeaux, INSERM U1211, Laboratoire Maladies Rares: Génétique et Métabolisme, Bordeaux, France
| | - Marie-Laure Vuillaume
- CHU Bordeaux, Hôpital Pellegrin, Department of Medical Genetics, Centre de Référence des Anomalies du Développement Embryonnaire, Bordeaux cedex, France.,Université de Bordeaux, INSERM U1211, Laboratoire Maladies Rares: Génétique et Métabolisme, Bordeaux, France
| | - Nada Houcinat
- CHU Bordeaux, Hôpital Pellegrin, Department of Medical Genetics, Centre de Référence des Anomalies du Développement Embryonnaire, Bordeaux cedex, France.,Université de Bordeaux, INSERM U1211, Laboratoire Maladies Rares: Génétique et Métabolisme, Bordeaux, France
| | - Julie Deforges
- CHU Bordeaux, Hôpital Pellegrin, Department of Medical Genetics, Centre de Référence des Anomalies du Développement Embryonnaire, Bordeaux cedex, France
| | - Julie Bouron
- CHU Bordeaux, Hôpital Pellegrin, Department of Medical Genetics, Centre de Référence des Anomalies du Développement Embryonnaire, Bordeaux cedex, France
| | - Sylvie Devès
- CHU Bordeaux, Hôpital Pellegrin, Department of Medical Genetics, Centre de Référence des Anomalies du Développement Embryonnaire, Bordeaux cedex, France
| | - Martine Le Merrer
- Institut Imagine, Hôpital Necker Enfants Malades, Department of Medical Genetics, INSERM U781, Université Paris Descartes-Sorbonne Paris Cité, Paris cedex, France
| | - Albert David
- CHU Nantes, Hôpital Mère-Enfant, Department of Medical Genetics, Nantes cedex, France
| | - David Geneviève
- CHRU Montpellier, Hôpital Arnaud de Villeneuve, Department of Medical Genetics, Université Montpellier INSERM U1183, CLAD Sud Languedoc-Roussillon, Montpellier cedex, France
| | - Fabienne Giuliano
- CHU Nice, Hôpital l'Archet 2, Department of Medical Genetics, Nice cedex, France
| | - Hubert Journel
- Centre Hospitalier Bretagne Atlantique, Department of Medical Genetics and Oncogenetics, Vannes cedex, France
| | - André Megarbane
- Al-Jawhara Center, Department of Medical Genetics, Arabian Gulf University, Manama, Kingdom of Bahrain
| | - Laurence Faivre
- CHU Dijon, Department of Medical Genetics, Centre de Référence Anomalies de Développement et Syndromes Malformatifs de l'inter-région Grand-Est, Hôpital d'Enfants, Dijon, France
| | - Nicolas Chassaing
- CHU Toulouse, Hôpital Purpan, Department of Medical Genetics, UDEAR, Université de Toulouse, Inserm, UPS, CNRS, Toulouse cedex, France
| | - Christine Francannet
- CHU Clermont-Ferrand, Hôpital d'Estaing, Department of Medical Genetics, Clermont-Ferrand cedex, France
| | - Elisabeth Sarrazin
- CHU de Fort de France, Hôpital Pierre Zobda-Quitman, Department of Neuropediatrics, Centre de Référence Caribéen des Maladies Rares Neurologiques et Neuromusculaires, Martinique, France
| | - Eva-Lena Stattin
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden
| | - Jacqueline Vigneron
- CHU Nancy, Maternité Régionale Adolphe Pinard, Department of Medical Genetics, Nancy cedex, France
| | - Danielle Leclair
- CHU Raymond Poincaré, Department of Physical Medicine and Rehabilitation, Centre de Référence Maladies Neuromusculaires, Garches, France
| | - Caroline Abadie
- CHRU Montpellier, Hôpital Arnaud de Villeneuve, Department of Medical Genetics, Université Montpellier INSERM U1183, CLAD Sud Languedoc-Roussillon, Montpellier cedex, France
| | - Pierre Sarda
- CHRU Montpellier, Hôpital Arnaud de Villeneuve, Department of Medical Genetics, Université Montpellier INSERM U1183, CLAD Sud Languedoc-Roussillon, Montpellier cedex, France
| | - Clarisse Baumann
- AP-HP, Hôpital Robert Debré, Department of Medical Genetics, CLAD Ile de France, Paris, France
| | - Marie-Ange Delrue
- CHU Bordeaux, Hôpital Pellegrin, Department of Medical Genetics, Centre de Référence des Anomalies du Développement Embryonnaire, Bordeaux cedex, France
| | - Benoit Arveiler
- CHU Bordeaux, Hôpital Pellegrin, Department of Medical Genetics, Centre de Référence des Anomalies du Développement Embryonnaire, Bordeaux cedex, France.,Université de Bordeaux, INSERM U1211, Laboratoire Maladies Rares: Génétique et Métabolisme, Bordeaux, France
| | - Didier Lacombe
- CHU Bordeaux, Hôpital Pellegrin, Department of Medical Genetics, Centre de Référence des Anomalies du Développement Embryonnaire, Bordeaux cedex, France.,Université de Bordeaux, INSERM U1211, Laboratoire Maladies Rares: Génétique et Métabolisme, Bordeaux, France
| | - Cyril Goizet
- CHU Bordeaux, Hôpital Pellegrin, Department of Medical Genetics, Centre de Référence des Anomalies du Développement Embryonnaire, Bordeaux cedex, France.,Université de Bordeaux, INSERM U1211, Laboratoire Maladies Rares: Génétique et Métabolisme, Bordeaux, France
| | - Isabelle Coupry
- Université de Bordeaux, INSERM U1211, Laboratoire Maladies Rares: Génétique et Métabolisme, Bordeaux, France
| |
Collapse
|
3
|
Catteruccia M, Vuillerot C, Vaugier I, Leclair D, Azzi V, Viollet L, Estournet B, Bertini E, Quijano-Roy S. Orthopedic Management of Scoliosis by Garches Brace and Spinal Fusion in SMA Type 2 Children. J Neuromuscul Dis 2015; 2:453-462. [PMID: 27858747 PMCID: PMC5240608 DOI: 10.3233/jnd-150084] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
BACKGROUND Scoliosis is the most debilitating issue in SMA type 2 patients. No evidence confirms the efficacy of Garches braces (GB) to delay definitive spinal fusion. OBJECTIVE Compare orthopedic and pulmonary outcomes in children with SMA type 2 function to management. METHOD We carried out a monocentric retrospective study on 29 SMA type 2 children who had spinal fusion between 1999 and 2009. Patients were divided in 3 groups: group 1-French patients (12 children) with a preventive use of GB; group 2-French patients (10 children) with use of GB after the beginning of the scoliosis curve; and group 3-Italian patients (7 children) with use of GB after the beginning of the scoliosis curve referred to our centre to perform orthopedic preoperative management. RESULTS Mean preoperative and postoperative Cobb angle were significantly lower in the group 1 of proactively braced than in group 2 or 3 (Anova p = 0.03; Kruskal Wallis test p = 0.05). Better surgical results were observed in patients with a minor preoperative Cobb angle (r = 0.92 p < 0.0001). Fewer patients in the group 1 proactively braced required trunk casts and/or halo traction and an additional anterior fusion in comparison with patients in the group 2 and 3. Moreover, major complications tend to be less in the group 1 proactively braced. No significant differences were found between groups in pulmonary outcome measures. CONCLUSIONS A proactive orthotic management may improve orthopedic outcome in SMA type 2. Further prospective studies comparing SMA management are needed to confirm these results. LEVEL OF EVIDENCE Therapeutic Level III. See Instructions to Authors on jbjs.org for a complete description of levels of evidence (Retrospective comparative study).
Collapse
Affiliation(s)
- Michela Catteruccia
- Unit of Neuromuscular and Neurodegenerative Disorders, Laboratory of molecular Medicine, Department of Neurosciences and Neurorehabilitation, Bambino Gesù Children's Research Hospital, IRCCS, Rome, Italy
| | - Carole Vuillerot
- Hospices Civils de Lyon,Hôpital Femme-Mère-Enfant, L'Escale, Service de Médecine Physique et de Réadaptation Pédiatrique, Bron, F-69500, France, Université de Lyon, Lyon, F-69000, France, CNRS UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique Santé, Pierre-Bénite, F-69310, France.,FILNEMUS, Réseau National Français de la Filière Neuromusculaire, France
| | - Isabelle Vaugier
- AP-HP, Raymond Poincaré Hôpital, INSERM CIC 14.29, 92380 Garches, France
| | - Danielle Leclair
- Assistance Publique des Hôpitaux de Paris (AP-HP), Service de Pédiatrie, Hôpital Raymond Poincaré, Garches, Hôpitaux Universitaires Paris-Ile-de-France Ouest, France.,Centre de Référence de Maladies Neuromusculaires Garches-Necker-Mondor-Hendaye (GNMH), France
| | - Viviane Azzi
- Assistance Publique des Hôpitaux de Paris (AP-HP), Service de Pédiatrie, Hôpital Raymond Poincaré, Garches, Hôpitaux Universitaires Paris-Ile-de-France Ouest, France.,Centre de Référence de Maladies Neuromusculaires Garches-Necker-Mondor-Hendaye (GNMH), France
| | - Louis Viollet
- Assistance Publique des Hôpitaux de Paris (AP-HP), Service de Pédiatrie, Hôpital Raymond Poincaré, Garches, Hôpitaux Universitaires Paris-Ile-de-France Ouest, France.,Centre de Référence de Maladies Neuromusculaires Garches-Necker-Mondor-Hendaye (GNMH), France
| | - Brigitte Estournet
- Assistance Publique des Hôpitaux de Paris (AP-HP), Service de Pédiatrie, Hôpital Raymond Poincaré, Garches, Hôpitaux Universitaires Paris-Ile-de-France Ouest, France.,Centre de Référence de Maladies Neuromusculaires Garches-Necker-Mondor-Hendaye (GNMH), France.,FILNEMUS, Réseau National Français de la Filière Neuromusculaire, France
| | - Enrico Bertini
- Unit of Neuromuscular and Neurodegenerative Disorders, Laboratory of molecular Medicine, Department of Neurosciences and Neurorehabilitation, Bambino Gesù Children's Research Hospital, IRCCS, Rome, Italy
| | - Susana Quijano-Roy
- Assistance Publique des Hôpitaux de Paris (AP-HP), Service de Pédiatrie, Hôpital Raymond Poincaré, Garches, Hôpitaux Universitaires Paris-Ile-de-France Ouest, France.,Centre de Référence de Maladies Neuromusculaires Garches-Necker-Mondor-Hendaye (GNMH), France.,Université de Versailles-St Quentin, U1179 UVSQ - INSERM, Montigny, France.,FILNEMUS, Réseau National Français de la Filière Neuromusculaire, France
| |
Collapse
|
4
|
Dubey JP, Quirk T, Pittt JA, Sundar N, Velmurugan GV, Kwok OCH, Leclair D, Hill R, Su C. Isolation and genetic characterization of Toxoplasma gondii from raccoons (Procyon lotor), cats (Felis domesticus), striped skunk (Mephitis mephitis), black bear (Ursus americanus), and cougar (Puma concolor) from Canada. J Parasitol 2008; 94:42-5. [PMID: 18372620 DOI: 10.1645/ge-1349.1] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
Viable Toxoplasma gondii was isolated by bioassay in mice from tissues of 2 feral cats (Felis domesticus), 2 raccoons (Procyon lotor), a skunk (Mephitis mephitis) trapped in remote locations in Manitoba, Canada, and a black bear (Ursus americanus) from Kuujjuaq, northern Quebec, Canada. Genotyping of these T. gondii isolates using polymorphisms at 10 nuclear markers including SAGI, SAG2, SAG3, BTUB, GRA6, c22-8, c29-2, L358, PK1, and an apicoplast marker Apico revealed 4 genotypes. None of the isolates was clonal archetypal Types I, II, and III found in the United States. These results are in contrast with the Type II genotype that is widespread in domestic animals and humans throughout the United States and Europe. This is the first genotyping of T. gondii isolates from this part of North America.
Collapse
Affiliation(s)
- J P Dubey
- United States Department of Agriculture, Agricultural Research Service, Animal and Natural Resources Institute, Animal Parasitic Diseases Laboratory, Building 1001, Beltsville, Maryland 20705-2350, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|